发明名称 Therapeutic regimen and methods for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency
摘要 Disclosed herein are therapeutic regimens for treating or ameliorating a visual disorder associate with an endogenous retinoid deficiency in a subject by administering a therapeutically effective amount of a synthetic retinal derivative or a pharmaceutically acceptable composition comprising a synthetic retinal derivative according to the therapeutic regimen which leads to local recovery of visual functions such as visual fields, visual acuity and retinal sensitivity, among others.
申请公布号 US9173856(B2) 申请公布日期 2015.11.03
申请号 US201113090215 申请日期 2011.04.19
申请人 QLT INC. 发明人 Strong H. Andrew;Cadden Suzanne
分类号 A61K31/215;A61K31/11;A61K9/00 主分类号 A61K31/215
代理机构 Ropes & Gray LLP 代理人 Ropes & Gray LLP
主权项 1. A method for treating a human patient suffering from the loss or impairment of vision caused by Leber Congenital Amaurosis (LCA), wherein said patient is deficient in endogenous 11-cis-retinal disorder, comprising the steps of: a) administering to the human patient an initial therapeutically effective dose of a synthetic retinal derivative selected from the group consisting of 9-cis-retinyl acetate, 9-cis-retinyl formate, 9-cis-retinyl succinate, 9-cis-retinyl citrate, 9-cis-retinyl ketoglutarate, 9-cis-retinyl fumarate, 9-cis-retinyl malate, 9-cis-retinyl oxaloacetate, 9-cis-retinyl propionate, 9-cis-retinyl butyrate, 9-cis-retinyl valerate, 9-cis-retinyl hexanoate, 9-cis-retinyl heptanoate, 9-cis-retinyl octanoate, 9-cis-retinyl nonanoate, 9-cis-retinyl decanoate, 9-cis-retinyl undecanoate, 9-cis-retinyl dodecanoate, 9-cis-retinyl oxalate, 9-cis-retinyl malonate, 9-cis-retinyl glutarate, 9-cis-retinyl adipate, 9-cis-retinyl pimelate, 9-cis-retinyl suberate, 9-cis-retinyl azelate, and 9-cis-retinyl sebacate, b) refraining from administering to the human patient an additional therapeutically effective dose of the synthetic retinal derivative for a resting interval, wherein the resting interval is a time period between 1 month and 14 months, c) administering to the human patient the additional therapeutically effective dose of the synthetic retinal derivative.
地址 Vancouver CA